SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G/A


UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)


Coherus Oncology, Inc.
(Name of Issuer)


Common Stock, $0.0001 par value per share
(Title of Class of Securities)


19249H103
(CUSIP Numbers)


03/31/2026
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐   Rule 13d-1(b)
☒   Rule 13d-1(c)
☐   Rule 13d-1(d)




SCHEDULE 13G/A
CUSIP Number(s):
19249H103


1 Names of Reporting Persons

Timothy G. Youngquist 2020 Irrevocable Trust
2 Check the appropriate box if a member of a Group (see instructions)

☐  (a)
☒  (b)
3SEC Use Only
4 Citizenship or Place of Organization

FLORIDA
Number of Shares Beneficially Owned by Each Reporting Person With:
5 Sole Voting Power: 12,750,800.00
6 Shared Voting Power: 0.00
7 Sole Dispositive Power: 12,750,800.00
8 Shared Dispositive Power: 0.00
9 Aggregate Amount Beneficially Owned by Each Reporting Person

12,750,800.00
10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐
11 Percent of class represented by amount in row (9)

8.3 %
12 Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage reported is based on 154,217,609 shares of the Issuer's common stock outstanding as of April 16, 2026, as reported in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 20, 2026. The shares reported herein are held by the Timothy G. Youngquist 2020 Irrevocable Trust, dated 2020, as amended and/or restated (the "Trust"), of which Trista Kragh is a trustee. Includes 460,000 shares of common stock underlying call options that constitute a right to acquire shares within 60 days for purposes of Rule 13d-3. For purposes of calculating the Reporting Person's percentage of class, such underlying shares are deemed outstanding. This Amendment No. 2 is filed solely to correct certain information in Amendment No. 1.



SCHEDULE 13G/A

Item 1. 
(a) Name of issuer:

Coherus Oncology, Inc.
(b) Address of issuer's principal executive offices:

333 Twin Dolphin Drive, Suite 600, Redwood City, CALIFORNIA, 94065
Item 2. 
(a) Name of person filing:

Timothy G. Youngquist 2020 Irrevocable Trust
(b) Address or principal business office or, if none, residence:

15581 Pine Ridge Road, Fort Myers, FL 33908
(c) Citizenship:

See Item 4 of the Cover Page.
(d) Title of class of securities:

Common Stock, $0.0001 par value per share
(e) CUSIP No.:

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)☐   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)☐   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)☐   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)☐   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
       please specify the type of institution:
(k)☐   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
 
Item 4.Ownership
(a) Amount beneficially owned:

See Item 9 of the Cover Page.
(b) Percent of class:

See Item 11 of the Cover Page.
(c) Number of shares as to which the person has:
  (i) Sole power to vote or to direct the vote:

See Item 5 of the Cover Page.

  (ii) Shared power to vote or to direct the vote:

See Item 6 of the Cover Page.

  (iii) Sole power to dispose or to direct the disposition of:

See Item 7 of the Cover Page.

  (iv) Shared power to dispose or to direct the disposition of:

See Item 8 of the Cover Page.

Item 5.Ownership of 5 Percent or Less of a Class.
 
Not Applicable
Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
 
Not Applicable
Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
 
Not Applicable
Item 8.Identification and Classification of Members of the Group.
 
Not Applicable
Item 9.Notice of Dissolution of Group.
 
Not Applicable

Item 10.Certifications:
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE 
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
Timothy G. Youngquist 2020 Irrevocable Trust
 Signature:Nolan Rheam
 Name/Title:Manager
 Date:05/15/2026